Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
humans (45) 45
hematology (43) 43
male (39) 39
female (38) 38
middle aged (37) 37
oncology (28) 28
adult (27) 27
aged (26) 26
adolescent (24) 24
leukemia (20) 20
transplantation (20) 20
acute myeloid leukemia (18) 18
cancer (16) 16
young adult (16) 16
retrospective studies (14) 14
stem cells (14) 14
aged, 80 and over (13) 13
analysis (13) 13
bone-marrow-transplantation (13) 13
prognosis (13) 13
survival rate (13) 13
chemistry (12) 12
hematology, oncology and palliative medicine (12) 12
hematopoietic stem cells (12) 12
leukemia, myeloid, acute - mortality (12) 12
metallurgy (11) 11
treatment outcome (11) 11
adults (10) 10
hematopoietic stem cell transplantation (10) 10
leukemia, myeloid, acute - drug therapy (10) 10
leukemia, myeloid, acute - therapy (10) 10
medicine & public health (10) 10
stem-cell transplantation (10) 10
survival (10) 10
leukemia, myeloid, acute - genetics (9) 9
patients (9) 9
relapse (9) 9
remission (9) 9
transplantation, homologous (9) 9
acute myeloid-leukemia (8) 8
chemotherapy (8) 8
electricity (8) 8
human necessities (8) 8
hygiene (8) 8
immunology (8) 8
medical or veterinary science (8) 8
myeloid leukemia (8) 8
preparations for medical, dental, or toilet purposes (8) 8
therapy (8) 8
basic electric elements (7) 7
disease-free survival (7) 7
medical prognosis (7) 7
outcomes (7) 7
physics (7) 7
research (7) 7
risk factors (7) 7
specific use of cosmetics or similar toiletpreparations (7) 7
acute myelogenous leukemia (6) 6
cord blood transplantation (6) 6
genetic aspects (6) 6
impact (6) 6
mutation (6) 6
oncology, experimental (6) 6
organic chemistry (6) 6
patient outcomes (6) 6
performing operations (6) 6
recurrence (6) 6
transporting (6) 6
versus-host-disease (6) 6
age factors (5) 5
allogeneic hematopoietic stem cell transplantation (5) 5
aml (5) 5
bone marrow (5) 5
cells (5) 5
cytarabine (5) 5
cytogenetics (5) 5
diseases (5) 5
dose-response relationship, drug (5) 5
follow-up studies (5) 5
graft-versus-host disease (5) 5
management (5) 5
medical colleges (5) 5
myelodysplastic syndrome (5) 5
original (5) 5
original article (5) 5
precursor cell lymphoblastic leukemia-lymphoma - mortality (5) 5
risk (5) 5
survival analysis (5) 5
trial (5) 5
unrelated donors (5) 5
acute lymphoblastic-leukemia (4) 4
adhesives (4) 4
allogeneic hematopoietic cell transplantation (4) 4
allografts (4) 4
antennas, i.e. radio aerials (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
blood (4) 4
child (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults
by Yasuda, Takahiko and Tsuzuki, Shinobu and Kawazu, Masahito and Hayakawa, Fumihiko and Kojima, Shinya and Ueno, Toshihide and Imoto, Naoto and Kohsaka, Shinji and Kunita, Akiko and Doi, Koichiro and Sakura, Toru and Yujiri, Toshiaki and Kondo, Eisei and Fujimaki, Katsumichi and Ueda, Yasunori and Aoyama, Yasutaka and Ohtake, Shigeki and Takita, Junko and Sai, Eirin and Taniwaki, Masafumi and Kurokawa, Mineo and Morishita, Shinichi and Fukayama, Masashi and Kiyoi, Hitoshi and Miyazaki, Yasushi and Naoe, Tomoki and Mano, Hiroyuki
Nature Genetics, ISSN 1061-4036, 05/2016, Volume 48, Issue 5, pp. 569 - 574
The oncogenic mechanisms underlying acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA; 15-39 years old) remain largely elusive. Here we... 
NIH 3T3 Cells | MEF2 Transcription Factors - genetics | Age Factors | Humans | Middle Aged | Child, Preschool | Infant | Male | RNA, Neoplasm | Young Adult | Oncogene Proteins, Fusion | HEK293 Cells | Trans-Activators - genetics | Aged, 80 and over | Adult | Female | Child | Infant, Newborn | Gene Fusion | Homeodomain Proteins - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Animals | Sequence Analysis, RNA | Adolescent | Aged | Mice | Immunoglobulin Heavy Chains - genetics | Cohort Studies | Development and progression | Genetic aspects | Acute lymphocytic leukemia | Identification and classification | Oncogenes | Research & development--R&D | Leukemia | Genomes | Kinases | Gene expression | Proteins | Studies | Genotype & phenotype | Archives & records | Medical prognosis | Mutation | Chromosomes | Age | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
by Kobayashi, Yukio and Yamauchi, Takahiro and Kiyoi, Hitoshi and Sakura, Toru and Hata, Tomoko and Ando, Kiyoshi and Watabe, Aiko and Harada, Akiko and Taube, Tillmann and Miyazaki, Yasushi and Naoe, Tomoki
Cancer Science, ISSN 1347-9032, 11/2015, Volume 106, Issue 11, pp. 1590 - 1595
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib... 
maximum tolerated dose | Polo‐like kinase 1 | Acute myeloid leukemia | Japanese | clinical trial phase I | Maximum tolerated dose | Polo-like kinase 1 | Clinical trial phase I | DIAGNOSIS | CELLS | MANAGEMENT | CANCER | THERAPY | ONCOLOGY | PRECLINICAL MODELS | RECOMMENDATIONS | BI 6727 | TARGETS | OUTCOMES | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Humans | Japan | Middle Aged | Pteridines - adverse effects | Male | Pteridines - pharmacokinetics | Pteridines - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Asian Continental Ancestry Group | Maximum Tolerated Dose | Antineoplastic Agents - adverse effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacokinetics | Appetite | Participation | Research funding | Toxicity | Myeloid leukemia | Leukemia | Clinical trials | Nausea | Patients | Stomatitis | Chemotherapy | Consent | Cell cycle | Hypokalemia | Sepsis | Remission | Pharmacokinetics | Neutropenia | Apoptosis | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen
by Hoshino, Takumi and Takada, Satoru and Hatsumi, Nahoko and Sakura, Toru
International Journal of Hematology, ISSN 0925-5710, 4/2019, Volume 109, Issue 4, pp. 463 - 469
Primary graft failure (PGF) is a lethal complication that occurs early after allogeneic stem cell transplantation (allo-SCT). Cord blood transplantation (CBT)... 
Primary graft failure | Anti-thymocyte globulin | Total body irradiation | Salvage | Medicine & Public Health | Hematology | Cord blood transplantation | Oncology | RISK-FACTORS | BONE-MARROW-TRANSPLANTATION | UNRELATED DONORS | ANTITHYMOCYTE GLOBULIN | PERIPHERAL-BLOOD | VERSUS-HOST-DISEASE | ENGRAFTMENT | STEM-CELL TRANSPLANTATION | HEMATOLOGY | APLASTIC-ANEMIA | Antimitotic agents | Dosage and administration | Transplantation | Antineoplastic agents | Leukemia | Stem cells | Feasibility studies | Neutrophils | Radiation | Stem cell transplantation | Patients | Blood | Rejection | Prostaglandins | Grafts | Fludarabine | Thymocytes | Globulins | Cord blood | Melphalan | Irradiation | Feasibility | Chimerism | Conditioning
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
by Takahashi, Takeshi and Usuki, Kensuke and Matsue, Kosei and Ohno, Hitoshi and Sakura, Toru and Imanaka, Ryota and Murakami, Masato and Ohwada, Shoichi and Takagi, Taiga and Sakajiri, Sakura
International Journal of Hematology, ISSN 0925-5710, 12/2019, Volume 110, Issue 6, pp. 665 - 674
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML) are associated with early relapse... 
Relapsed or refractory acute myeloid leukemia | FLT3 -ITD mutation | Medicine & Public Health | Hematology | Oncology | Quizartinib | Acute myeloid leukemia | FLT3 inhibitor | Tyrosine | Relapse | Oncology, Experimental | Analysis | Research | Cancer | Diseases | Effectiveness | Arrhythmia | Myeloid leukemia | Leukemia | Kinases | Survival | Patients | Confidence intervals | Refractory materials | Remission | Flt3 protein | Safety | Mutation | Protein-tyrosine kinase | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia
by Gotoh, Nanami and Saitoh, Takayuki and Takahashi, Noriyuki and Kasamatsu, Tetsuhiro and Minato, Yusuke and Lobna, Alkebsi and Oda, Tsukasa and Hoshino, Takumi and Sakura, Toru and Shimizu, Hiroaki and Takizawa, Makiko and Handa, Hiroshi and Yokohama, Akihiko and Tsukamoto, Norifumi and Murakami, Hirokazu
International Journal of Hematology, ISSN 0925-5710, 09/2018, Volume 108, Issue 3, pp. 246 - 253
Recent studies have shown that tumors of relapsed acute myeloid leukemia (AML) present additional genetic mutations compared to the primary tumors. The base... 
Polymorphisms | Acute myeloid leukemia | Base excision repair | DNA damage | OGG1 | AML | CELLS | CLONAL EVOLUTION | CANCER | IN-VIVO | 8-HYDROXYGUANINE | GENERATION | DNA-REPAIR | PROTEINS | HEMATOLOGY | Medical colleges | Relapse | Gene mutations | Genetic aspects | Medicine, Preventive | Risk factors | Genetic polymorphisms | Diseases | Preventive health services | XRCC1 protein | Statistical analysis | Myeloid leukemia | Leukemia | Patients | Polymerase chain reaction | Confidence intervals | Genotype & phenotype | Restriction fragment length polymorphism | Genotyping | OGG1 protein | Remission | Adults | Mutation | Polymorphism | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Extramedullary Relapses after Allogeneic Stem Cell Transplant (allo-SCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL)
by Shimizu, Hiroaki and Ishizaki, Takuma and Hatsumi, Nahoko and Takada, Satoru and Yokohama, Akihiko and Saitoh, Takayuki and Sakura, Toru and Handa, Hiroshi
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5690 - 5690
Background: Extramedullary (EM) relapses were sometimes observed in acute leukemia patients both after chemotherapy and allo-SCT. Our recent study described... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia
by Kobayashi, Yukio and Sakura, Toru and Miyawaki, Shuichi and Toga, Kazuyuki and Sogo, Shinji and Heike, Yuji
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 07/2017, Volume 66, Issue 7, pp. 851 - 863
Wilms' tumor 1 (WT1) is a promising target of new immunotherapies for acute myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide... 
Helper peptide | OCV-501 | Cancer vaccine | WT1 | Acute myeloid leukemia | Immunotherapy | CD4(+) T-CELLS | INDUCTION | IMMUNOLOGY | CANCER | TUMOR-ANTIGEN | RESPONSES | MELANOMA | ONCOLOGY | EPITOPE LONG PEPTIDE | LYMPHOCYTES | HLA-A2 Antigen - genetics | Cancer Vaccines - pharmacology | Humans | Middle Aged | Male | Th1 Cells - immunology | Dose-Response Relationship, Drug | T-Lymphocytes, Cytotoxic - drug effects | WT1 Proteins - pharmacology | WT1 Proteins - immunology | Aged, 80 and over | Female | Leukemia, Myeloid, Acute - therapy | T-Lymphocytes, Cytotoxic - immunology | Th1 Cells - drug effects | WT1 Proteins - administration & dosage | Cancer Vaccines - administration & dosage | Vaccines, Subunit - immunology | HLA-DR beta-Chains - genetics | Remission Induction | Cancer Vaccines - immunology | Maximum Tolerated Dose | Vaccines, Subunit - pharmacology | Lymphocyte Activation - drug effects | Vaccines, Subunit - administration & dosage | Cell Line, Tumor | Aged | Cohort Studies | Peptides | Oncology, Experimental | Clinical trials | Research | Vaccines | T cells | Cancer | Cytolytic activity | Hypersensitivity (delayed) | Myeloid leukemia | Leukemia | Hypersensitivity | Cytotoxicity | Leukocytes (mononuclear) | Pharmacology | Lymphocytes T | In vitro testing | Blast | Wilms' tumor | Patients | WT1 protein | Immunology | Lymphocytes B | Lymphocytes | Peripheral blood mononuclear cells | Remission | Histocompatibility antigen HLA | Blast cells | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study
by Usuki, Kensuke and Sakura, Toru and Kobayashi, Yukio and Miyamoto, Toshihiro and Iida, Hiroatsu and Morita, Satoshi and Bahceci, Erkut and Kaneko, Masahito and Kusano, Mikiko and Yamada, Shunsuke and Takeshita, Shigeru and Miyawaki, Shuichi and Naoe, Tomoki
Cancer Science, ISSN 1347-9032, 10/2018, Volume 109, Issue 10, pp. 3235 - 3244
Gilteritinib, a novel, highly specific, potent fms‐like tyrosine kinase 3/AXL inhibitor, demonstrated antileukemic activity in patients with... 
fms‐like tyrosine kinase 3 | mutation | hematopoiesis | acute myeloid leukemia | bone marrow | fms-like tyrosine kinase 3 | INTERNAL TANDEM DUPLICATION | TYROSINE KINASE AXL | CONTROLLED-TRIAL | MULTICENTER | ACTIVATION | FLT3 INHIBITOR | SORAFENIB | ONCOLOGY | THERAPEUTIC TARGET | MUTATIONS | QUIZARTINIB | Thrombocytopenia - epidemiology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Japan - epidemiology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Pyrazines - therapeutic use | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Neoplasm Recurrence, Local - blood | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Creatine Kinase - blood | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Thrombocytopenia - chemically induced | Aniline Compounds - pharmacokinetics | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Pyrazines - pharmacokinetics | Aged | Aniline Compounds - therapeutic use | Tyrosine | Research | Creatine | Creatine kinase | Oncology, Experimental | Cancer | Leukemia | Kinases | Blood | Axl protein | Syncope | Consent | Remission | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Thrombocytopenia | Research funding | Myeloid leukemia | Patients | L-Lactate dehydrogenase | Studies | Medical prognosis | Lysis | Response rates | Lactic acid | Mutation | Pharmacokinetics | Platelets | Acute myeloid leukemia | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A synthesized boundary condition for wave-based room acoustics simulations using ensemble averaged impedance measured in-situ
by Otsuru, Toru and Tomiku, Reiji and Okamoto, Noriko and Saigo, Sakura and Yamauchi, Saki
Journal of the Acoustical Society of America, ISSN 0001-4966, 10/2016, Volume 140, Issue 4, pp. 3174 - 3174
The importance of wave-based room acoustics simulation has been increasing in various fields of researches and design-stages. The problem remained, however, is... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study
by Kawashima, Naomi and Ishikawa, Yuichi and Atsuta, Yoshiko and Sugiura, Isamu and Sawa, Masashi and Dobashi, Nobuaki and Yokoyama, Hisayuki and Doki, Noriko and Tomita, Akihiro and Kiguchi, Toru and Koh, Shiro and Kanamori, Heiwa and Iriyama, Noriyoshi and Kohno, Akio and Moriuchi, Yukiyoshi and Asada, Noboru and Hirano, Daiki and Togitani, Kazuto and Sakura, Toru and Hagihara, Maki and Tomikawa, Tatsuki and Yokoyama, Yasuhisa and Asou, Norio and Ohtake, Shigeki and Matsumura, Itaru and Miyazaki, Yasushi and Naoe, Tomoki and Kiyoi, Hitoshi
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 438 - 438
Abstract Background: Recent advance in genetic analysis has revealed that many mutations are associated with the development, progression and/or prognosis of... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Clinical Significance of Clonal Cytogenetic Heterogeneity (CCH) at Diagnosis in Adult Patients with Acute Lymphoblastic Leukemia (ALL)
by Shimizu, Hiroaki and Hatsumi, Nahoko and Takada, Satoru and Ishizaki, Takuma and Yokohama, Akihiko and Saitoh, Takayuki and Sakura, Toru and Handa, Hiroshi
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2820 - 2820
Abstract Background:Although cytogenetic abnormalities at diagnosis are recognized as one of the most potent prognostic factors in acute leukemia patients, CCH... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome
by Shimomura, Yoshimitsu and Hara, Masahiko and Tachibana, Takayoshi and Ohashi, Kazuteru and Sakura, Toru and Fukuda, Takahiro and Nakazawa, Hideyuki and Iwato, Koji and Kanda, Yoshinobu and Ikeda, Takashi and Eto, Tetsuya and Kanda, Junya and Ichinohe, Tatsuo and Atsuta, Yoshiko and Ishikawa, Takayuki and Ishiyama, Ken
British Journal of Haematology, ISSN 0007-1048, 07/2019, Volume 186, Issue 1, pp. 86 - 90
Summary Though second allogenic haematopoietic stem cell transplantation (HSCT) is considered a curative treatment option after myelodysplastic syndrome (MDS)... 
performance status | myelodysplastic syndrome | allogeneic haematopoietic stem cell transplantation | second allogeneic haematopoietic stem cell transplantation | early relapse | ACUTE-LEUKEMIA | BONE-MARROW-TRANSPLANTATION | HEMATOLOGY | SOCIETY | BLOOD | Relapse | Care and treatment | Patient outcomes | Stem cells | Transplantation | Epidemiology | Hematopoietic stem cells | Diseases | Confidence intervals | Medical prognosis | Stem cell transplantation | Health risk assessment | Survival | Myelodysplastic syndrome
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation
by Kimura, Fumihiko and Kanda, Junya and Ishiyama, Ken and Yabe, Toshio and Yoshifuji, Kota and Fukuda, Takahiro and Ozawa, Yukiyasu and Iwato, Koji and Eto, Tetsuya and Mori, Takehiko and Uchida, Naoyuki and Ota, Shuichi and Sakura, Toru and Ichinohe, Tatsuo and Atsuta, Yoshiko and Kanda, Yoshinobu and Japan Soc Hematopoietic Cell Trans and donor/source working group of the Japan Society for Hematopoietic Cell Transplantation and for the donor/source working group of the Japan Society for Hematopoietic Cell Transplantation
Bone Marrow Transplantation, ISSN 0268-3369, 2019, Volume 54, Issue 10, pp. 1676 - 1685
The effects of ABO incompatibility on hematopoietic stem cell transplantation remain controversial. Large cohorts are required to obtain findings that allow... 
ALLELE MISMATCH COMBINATIONS | ONCOLOGY | DONOR | JAPAN | REGARDLESS | SCRIPTS | IMMUNOLOGY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | VERSUS-HOST-DISEASE | TRUMP DATA | TRANSPLANTATION | Graft versus host reaction | Usage | Transplantation | Patient outcomes | Risk factors | Hematopoietic stem cells | Incompatibility | Syngeneic grafts | Erythrocytes | Bone marrow transplantation | Stem cell transplantation | ABO system | Leukocytes (neutrophilic) | Survival | Hemopoiesis | Red blood cells | Stem cells | Bone marrow | Platelets | Blood groups
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study
by Takeshita, Akihiro and Asou, Norio and Atsuta, Yoshiko and Sakura, Toru and Ueda, Yasunori and Sawa, Masashi and Dobashi, Nobuaki and Taniguchi, Yasuhiro and Suzuki, Rikio and Nakagawa, Masaru and Tamaki, Shigehisa and Hagihara, Maki and Fujimaki, Katsumichi and Furumaki, Hiroaki and Obata, Yukako and Fujita, Hiroyuki and Yanada, Masamitsu and Maeda, Yoshinobu and Usui, Noriko and Kobayashi, Yukio and Kiyoi, Hitoshi and Ohtake, Shigeki and Matsumura, Itaru and Naoe, Tomoki and Miyazaki, Yasushi and Japanese Adult Leukemia Study Grp and Japanese Adult Leukemia Study Group and and the Japanese Adult Leukemia Study Group
Leukemia, ISSN 0887-6924, 02/2019, Volume 33, Issue 2, pp. 358 - 370
Between April 2004 and December 2010, we conducted a prospective randomized controlled study comparing tamibarotene with all-trans retinoic acid (ATRA) in the... 
TRIAL | EFFICACY | ONCOLOGY | ANTHRACYCLINE | CONSOLIDATION THERAPY | RESISTANCE | RISK | TRANS-RETINOIC ACID | CYTARABINE | HEMATOLOGY | CHEMOTHERAPY | ARSENIC TRIOXIDE | Benzoates - therapeutic use | Leukemia, Promyelocytic, Acute - pathology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Tetrahydronaphthalenes - therapeutic use | Male | Survival Rate | Neoplasm Recurrence, Local - mortality | Remission Induction | Neoplasm Recurrence, Local - pathology | Young Adult | Adolescent | Leukemia, Promyelocytic, Acute - mortality | Adult | Female | Aged | Leukemia, Promyelocytic, Acute - drug therapy | Research | Health aspects | Oncology, Experimental | Tretinoin | Cancer | Risk groups | Complications | Leukemia | Maintenance | Leukocytes | Survival | Patients | Hemopoiesis | Promyeloid leukemia | White blood cells | Chemotherapy | Randomization | Remission | Retinoic acid | Acute promyeloid leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60–69 years with myelodysplastic syndrome
by Itonaga, Hidehiro and Ishiyama, Ken and Aoki, Kazunari and Aoki, Jun and Ishikawa, Takayuki and Uchida, Naoyuki and Ohashi, Kazuteru and Ueda, Yasunori and Fukuda, Takahiro and Sakura, Toru and Ohno, Yuju and Iwato, Koji and Okumura, Hirokazu and Kondo, Tadakazu and Ichinohe, Tatsuo and Takanashi, Minoko and Atsuta, Yoshiko and Miyazaki, Yasushi
Annals of Hematology, ISSN 0939-5555, 6/2019, Volume 98, Issue 6, pp. 1367 - 1381
We conducted a nationwide retrospective study to evaluate the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 651 patients aged... 
Allogeneic hematopoietic stem cell transplantation | Medicine & Public Health | Hematology | Oncology | GVHD-free and relapse-free survival | Elderly | Myelodysplastic syndrome | Transplantation | Analysis | Leukemia | Patient outcomes | Hematopoietic stem cells | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia
by Yanada, Masamitsu and Mori, Jinichi and Aoki, Jun and Masuko, Masayoshi and Harada, Kaito and Uchida, Naoyuki and Doki, Noriko and Fukuda, Takahiro and Sakura, Toru and Kanamori, Heiwa and Sawa, Masashi and Kondo, Tadakazu and Katayama, Yuta and Kanda, Junya and Ichinohe, Tatsuo and Atsuta, Yoshiko and Yano, Shingo
Annals of Hematology, ISSN 0939-5555, 9/2019, Volume 98, Issue 9, pp. 2179 - 2186
The prognosis of patients with acute myeloid leukemia (AML) is dismal after experiencing multiple relapses. This study retrospectively analyzed outcomes of... 
Medicine & Public Health | Hematology | Multiple relapses | Allogeneic hematopoietic cell transplantation | Relapsed | Oncology | Acute myeloid leukemia | AML | MANAGEMENT | ACUTE MYELOGENOUS LEUKEMIA | ADULTS | SCRIPTS | OUTCOMES | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | TRUMP DATA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older
by Konuma, Takaaki and Tsukada, Nobuhiro and Kanda, Junya and Uchida, Naoyuki and Ohno, Yuju and Miyakoshi, Shigesaburo and Kanamori, Heiwa and Hidaka, Michihiro and Sakura, Toru and Onizuka, Makoto and Kobayashi, Naoki and Sawa, Masashi and Eto, Tetsuya and Matsuhashi, Yoshiko and Kato, Koji and Ichinohe, Tatsuo and Atsuta, Yoshiko and Miyamura, Koichi and Japan Soc Hematopoietic Cell Trans and Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation
American Journal of Hematology, ISSN 0361-8609, 05/2016, Volume 91, Issue 5, pp. E284 - E292
Older recipient and donor age were associated with higher incidences of severe graft‐versus‐host disease (GVHD) and mortality after allogeneic hematopoietic... 
JAPAN SOCIETY | REDUCED-INTENSITY | ADULT PATIENTS | ACUTE LYMPHOBLASTIC-LEUKEMIA | INTERNATIONAL BLOOD | ACUTE MYELOID-LEUKEMIA | DONOR TRANSPLANTATION | COMPARABLE SURVIVAL | HEMATOLOGY | VERSUS-HOST-DISEASE | HEMATOLOGIC MALIGNANCIES | Japan - epidemiology | Recurrence | Graft vs Host Disease - epidemiology | Peripheral Blood Stem Cell Transplantation - adverse effects | Age Factors | Humans | Middle Aged | Cord Blood Stem Cell Transplantation - statistics & numerical data | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Living Donors | HLA Antigens - genetics | Cause of Death | Bone Marrow Transplantation - statistics & numerical data | Incidence | Cord Blood Stem Cell Transplantation - adverse effects | Myelodysplastic Syndromes - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | ABO Blood-Group System - genetics | Female | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Severity of Illness Index | Blood Platelets | Neutrophils | Proportional Hazards Models | Peripheral Blood Stem Cell Transplantation - mortality | Graft Survival | Treatment Outcome | Peripheral Blood Stem Cell Transplantation - statistics & numerical data | Leukemia, Myeloid, Acute - mortality | Bone Marrow Transplantation - mortality | Myelodysplastic Syndromes - mortality | Bone Marrow Transplantation - adverse effects | Aged | Cord Blood Stem Cell Transplantation - mortality | Histocompatibility | Mortality | Leukemia | Patient outcomes | Stem cells | Bone marrow | Transplantation | Comparative analysis | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights